Published • loading... • Updated
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
Increased All-Cash Tender Offer Price of $21.80 per share – or $153.2 Million New Tender Offer Price Represents 21.1% Premium to Prior OfferLAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an Amended and Restated Agreement and Plan more... The post Assertio Announces Amended and Restated Merger Agre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
